<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03065582</url>
  </required_header>
  <id_info>
    <org_study_id>IRB # 9695</org_study_id>
    <nct_id>NCT03065582</nct_id>
  </id_info>
  <brief_title>The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects</brief_title>
  <official_title>The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visible light is known to induce pigmentation in darker skin types. The investigators aim to
      study the effects of visible light on the skin after topical application of sunscreen plus
      antioxidant.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diffuse reflectance spectroscopy</measure>
    <time_frame>Baseline- immediately after irradiation to assess immediate pigment darkening</time_frame>
    <description>Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>photography</measure>
    <time_frame>Baseline-immediately after irradiation to assess immediate pigment darkening</time_frame>
    <description>Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>investigator's global assessment score</measure>
    <time_frame>Baseline- Immediately after irradiation to assess immediate pigment darkening</time_frame>
    <description>The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffuse reflectance spectroscopy</measure>
    <time_frame>24 hours after irradiation to assess persistent pigment darkening</time_frame>
    <description>Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>photography</measure>
    <time_frame>24 hours after irradiation to assess persistent pigment darkening</time_frame>
    <description>Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's global assessment score</measure>
    <time_frame>24 hours after irradiation to assess persistent pigment darkening</time_frame>
    <description>The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffuse reflectance spectroscopy</measure>
    <time_frame>7 days after irradiation to assess delayed tanning</time_frame>
    <description>Diffuse reflectance spectroscopy is a non-invasive objective measure of pigmentation based on reflectance patterns of the irradiated skin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photography</measure>
    <time_frame>7 days after irradiation to assess delayed tanning</time_frame>
    <description>Cross polarized photography is used to document pigmentation non-invasively and reduce surface glare of the skin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator global assessment score</measure>
    <time_frame>7 days after irradiation to assess delayed tanning</time_frame>
    <description>The investigator's global assessment score is a non-invasive subjective measure of pigmentation in which investigators assign a value ranging between 0, corresponding with no hyperpigmentation, to 5, or severe or dark hyperpigmentation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological effects</measure>
    <time_frame>24 hours after irradiation</time_frame>
    <description>biopsy with melanocyte and melanin stains to assess pigmentation</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pigmentation</condition>
  <arm_group>
    <arm_group_label>Sunscreen application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will undergo topical application of 3 products and an additional site will serve as a control</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Product A</intervention_name>
    <description>topical application sunscreen containing topical antioxidants and sunscreen filters</description>
    <arm_group_label>Sunscreen application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Product B</intervention_name>
    <description>topical application of product A without topical antioxidants</description>
    <arm_group_label>Sunscreen application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Product C</intervention_name>
    <description>Topical application of antioxidants only</description>
    <arm_group_label>Sunscreen application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No product applied</description>
    <arm_group_label>Sunscreen application</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age 18 and older

          -  Patients Fitzpatrick skin phototype IV-VI

          -  Patient able to understand requirements of the study and risks involved

          -  Patient able to sign a consent form

        Exclusion Criteria:

          -  A recent history of vitiligo, melasma, and other disorders of pigmentation with the
             exception of post inflammatory hyperpigmentation

          -  A known history of photodermatoses

          -  A known history of melanoma or non-melanoma skin cancers

          -  Those planning on going to the tanning parlors

          -  Using any of the photosensitizing medication within the visible light range or
             additional medications at the discretion of the investigator (examples include (but
             not limited to) thiazide diuretics, regular use of NSAIDs, hydroxychloroquine, or
             voriconazole)

          -  A woman who is lactating, pregnant, or planning to become pregnant

          -  Patient planning on exposing the irradiated or control areas to the sun

          -  known allergy to anesthetics (lidocaine or epinephrine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iltefat Hamzavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin. Photochem Photobiol. 2008 Mar-Apr;84(2):450-62. doi: 10.1111/j.1751-1097.2007.00286.x. Epub 2008 Jan 29. Review.</citation>
    <PMID>18248499</PMID>
  </reference>
  <reference>
    <citation>Kollias N, Baqer A. An experimental study of the changes in pigmentation in human skin in vivo with visible and near infrared light. Photochem Photobiol. 1984 May;39(5):651-9.</citation>
    <PMID>6739557</PMID>
  </reference>
  <reference>
    <citation>Porges SB, Kaidbey KH, Grove GL. Quantification of visible light-induced melanogenesis in human skin. Photodermatol. 1988 Oct;5(5):197-200.</citation>
    <PMID>3222167</PMID>
  </reference>
  <reference>
    <citation>Mahmoud BH, Ruvolo E, Hexsel CL, Liu Y, Owen MR, Kollias N, Lim HW, Hamzavi IH. Impact of long-wavelength UVA and visible light on melanocompetent skin. J Invest Dermatol. 2010 Aug;130(8):2092-7. doi: 10.1038/jid.2010.95. Epub 2010 Apr 22.</citation>
    <PMID>20410914</PMID>
  </reference>
  <reference>
    <citation>Duteil L, Cardot-Leccia N, Queille-Roussel C, Maubert Y, Harmelin Y, Boukari F, Ambrosetti D, Lacour JP, Passeron T. Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure. Pigment Cell Melanoma Res. 2014 Sep;27(5):822-6. doi: 10.1111/pcmr.12273. Epub 2014 Jul 25.</citation>
    <PMID>24888214</PMID>
  </reference>
  <reference>
    <citation>Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):514-9.</citation>
    <PMID>9012815</PMID>
  </reference>
  <reference>
    <citation>Boukari F, Jourdan E, Fontas E, Montaudié H, Castela E, Lacour JP, Passeron T. Prevention of melasma relapses with sunscreen combining protection against UV and short wavelengths of visible light: a prospective randomized comparative trial. J Am Acad Dermatol. 2015 Jan;72(1):189-90.e1. doi: 10.1016/j.jaad.2014.08.023. Epub 2014 Oct 22.</citation>
    <PMID>25443629</PMID>
  </reference>
  <reference>
    <citation>Wang SQ, Osterwalder U, Jung K. Ex vivo evaluation of radical sun protection factor in popular sunscreens with antioxidants. J Am Acad Dermatol. 2011 Sep;65(3):525-30. doi: 10.1016/j.jaad.2010.07.009. Epub 2011 May 31.</citation>
    <PMID>21624700</PMID>
  </reference>
  <reference>
    <citation>Kunisada M, Sakumi K, Tominaga Y, Budiyanto A, Ueda M, Ichihashi M, Nakabeppu Y, Nishigori C. 8-Oxoguanine formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin carcinogenesis. Cancer Res. 2005 Jul 15;65(14):6006-10.</citation>
    <PMID>16024598</PMID>
  </reference>
  <reference>
    <citation>Herrling T, Jung K, Fuchs J. Measurements of UV-generated free radicals/reactive oxygen species (ROS) in skin. Spectrochim Acta A Mol Biomol Spectrosc. 2006 Mar 13;63(4):840-5.</citation>
    <PMID>16543118</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>February 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <last_update_submitted>February 22, 2017</last_update_submitted>
  <last_update_submitted_qc>February 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Iltefat Hamzavi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Sunscreening Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

